Clinical trials: Nonfluent Progressive Aphasia
Predicted Tauopathies, Including, Progressive Supranuclear Palsy
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology…
- Conditions
- Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome
- Trial name
- NCT01056965
- Testing
- davunetide (AL-108, NAP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Primary Progressive Aphasia, Nonfluent Progressive Aphasia
Language Treatment for Progressive Aphasia
Progressive aphasia is characterized by a steady and progressive loss of language skills in the presence of relatively preserved memory, attention, and thinking.
- Conditions
- Primary Progressive Aphasia, Nonfluent Progressive Aphasia, Semantic Dementia
- Trial name
- NCT00957710
- Testing
- Errorless learning
- Where
- Canada
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Baycrest
Alzheimer's Disease, Primary Progressive Non-fluent Aphasia
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD).
- Conditions
- Alzheimer's Disease, Primary Progressive Non-fluent Aphasia, Frontotemporal Dementia (FTD)
- Trial name
- MINT-01 (NCT02912936)
- Testing
- Ketogenic medium chain triglyceride drink (MCT drink)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia
Primary Progressive Nonfluent Aphasia
Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia
Nonfluent/agrammatic variant primary progressive aphasia (nf/avPPA) is a fatal neurodegenerative disease that begins with isolated language deficits. There is currently no cure or treatment for this disease.
- Trial name
- NCT03153540
- Testing
- Active iTBS
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of British Columbia